NCT05004805View on ClinicalTrials.gov

COVID-19 Methylene Blue Antiviral Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 6, 2021

Primary Completion Date

December 12, 2021

Study Completion Date

December 12, 2021

Conditions
Covid19
Interventions
DRUG

Methylene Blue

MB administered topically as a 0.02% solution nasal spray in COVID-19 patients requiring hospitalization.

DRUG

Saline nasal spray

Saline administered topically as nasal spray in COVID-19 patients requiring hospitalization.

Trial Locations (1)

664049

Irkutsk Regional Hospital, Irkutsk

All Listed Sponsors
collaborator

Irkutsk State Medical University

OTHER

lead

Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences

OTHER_GOV

NCT05004805 - COVID-19 Methylene Blue Antiviral Treatment | Biotech Hunter | Biotech Hunter